The Motley Fool reports that biotech stocks surged in 2025, driven by FDA approvals and a doubling of longevity investment to $8.49 billion.
The typical biotech playbook is straightforward but risky: Raise large amounts of capital with an initial public offering, burn cash while navigating clinical trials, then submit a new drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results